Cargando…
Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group
Von Hippel-Lindau (VHL) disease is an autosomal dominant hereditary cancer syndrome that predisposes affected individuals to the development of multiple benign and malignant tumors. One of the main manifestations of VHL is renal cell carcinoma (RCC). RCC is increasingly being treated with targeted t...
Autores principales: | Oudard, Stéphane, Elaidi, Reza, Brizard, Mara, Rest, Céline Le, Caillet, Valérie, Deveaux, Sophie, Benoit, Gérard, Corréas, Jean-Michel, Benoudiba, Farida, David, Philippe, Gaudric, Alain, Hammel, Pascal, Joly, Dominique, Timsit, Marc Olivier, Méjean, Arnaud, Richard, Stéphane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356738/ https://www.ncbi.nlm.nih.gov/pubmed/27852035 http://dx.doi.org/10.18632/oncotarget.13301 |
Ejemplares similares
-
Von Hippel-Lindau Disease
por: Hes, Frederik J, et al.
Publicado: (2005) -
Sunitinib Treatment for Metastatic Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease
por: Kim, Ho Cheol, et al.
Publicado: (2013) -
A retrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease
por: Yuan, Gang, et al.
Publicado: (2018) -
Von Hippel-Lindau Disease and the Eye
por: Karimi, Saeed, et al.
Publicado: (2020) -
A Review of Von Hippel-Lindau Syndrome
por: Varshney, Neha, et al.
Publicado: (2017)